Last 7 days
0.2%
Last 30 days
2.5%
Last 90 days
31.4%
Trailing 12 Months
-1.2%
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
GILD | 99.8B | 27.3B | -4.19% | 39.66% | 21.72 | 3.66 | -0.09% | -26.23% |
MRNA | 58.1B | 19.3B | -4.61% | -16.03% | 6.95 | 3.02 | 4.29% | -31.47% |
INCY | 15.6B | 3.4B | -10.55% | -10.18% | 45.92 | 4.61 | 13.67% | -64.09% |
EXAS | 11.8B | 2.1B | 2.51% | -1.24% | -18.91 | 5.66 | 17.95% | -4.68% |
MID-CAP | ||||||||
EXEL | 6.0B | 1.6B | 6.39% | -14.17% | 32.84 | 3.72 | 12.27% | -21.11% |
SYNH | 3.6B | 5.4B | -7.30% | -56.29% | 13.33 | 0.66 | 3.46% | 13.48% |
DNLI | 3.1B | 108.5M | -21.66% | -32.82% | -9.55 | 28.71 | 122.90% | -12.19% |
ARWR | 2.6B | 278.3M | -26.06% | -48.44% | -16.69 | 9.26 | 92.72% | 15.56% |
SMALL-CAP | ||||||||
AVXL | 680.4M | - | -13.75% | -31.50% | -13.59 | 291.16 | -34.21% | -22.31% |
NVAX | 519.7M | 2.0B | -33.63% | -92.58% | -0.79 | 0.26 | 72.89% | 62.27% |
PGEN | 199.8M | 80.7M | -24.99% | -55.14% | 7.06 | 4.15 | 13.30% | 130.72% |
SRNE | 143.9M | 60.3M | -71.28% | -88.95% | -0.29 | 2.39 | 17.51% | -38.93% |
TENX | 15.6M | - | -26.15% | -25.71% | -0.24 | - | - | -67.11% |
NNVC | 14.4M | - | -6.77% | -46.09% | -2.09 | - | - | 20.96% |
Income Statement (Last 12 Months) | ||||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Revenue | 3.9% | 2,084,279,000 | 2,005,096,000 | 1,938,402,000 | 1,851,581,000 | 1,767,087,000 |
Cost Of Revenue | 5.1% | 574,394,000 | 546,300,000 | 514,101,000 | 483,469,000 | 458,757,000 |
S&GA Expenses | -8.1% | 846,011,000 | 920,104,000 | 929,024,000 | 907,929,000 | 861,889,000 |
R&D Expenses | 1.5% | 393,400,000 | 387,586,000 | 372,129,000 | 372,281,000 | 385,600,000 |
EBITDA | 15.7% | -514,945,333 | -611,176,333 | -633,140,333 | -644,919,000 | - |
EBITDA Margin | 18.9% | -0.25 | -0.30 | -0.44 | -0.35 | - |
Earnings Before Taxes | 13.0% | -632,570,000 | -727,497,000 | -746,416,000 | -751,489,000 | -842,506,000 |
EBT Margin | 16.4% | -0.30 | -0.36 | -0.52 | -0.41 | - |
Interest Expenses | 7.1% | 19,634,000 | 18,330,000 | 18,885,000 | 18,744,000 | 18,606,000 |
Net Income | 13.0% | -623,506,000 | -716,372,000 | -734,549,000 | -745,398,000 | -595,625,000 |
Net Income Margin | 16.3% | -0.30 | -0.36 | -0.51 | -0.40 | - |
Free Cahsflow | 12.6% | -438,021,000 | -501,146,000 | -495,227,000 | -355,232,000 | - |
Balance Sheet | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Assets | -1.3% | 6,227 | 6,307 | 6,437 | 6,491 | 6,685 |
Current Assets | -6.3% | 982 | 1,049 | 1,102 | 1,215 | 1,426 |
Cash Equivalents | 3.1% | 242 | 235 | 213 | 190 | 315 |
Inventory | 3.1% | 118 | 115 | 115 | 113 | 105 |
Net PPE | 10.0% | 685 | 623 | 580 | - | - |
Goodwill | 0.0% | 2,346 | 2,345 | 2,346 | 2,335 | 2,335 |
Liabilities | -0.4% | 3,184 | 3,198 | 3,228 | 3,232 | 3,297 |
Current Liabilities | -2.6% | 413 | 424 | 443 | 481 | 517 |
Shareholder's Equity | -2.1% | 3,043 | 3,109 | 3,209 | 3,258 | 3,388 |
Retained Earnings | -4.1% | -3,265 | -3,137 | -2,988 | -2,822 | -2,641 |
Additional Paid-In Capital | 0.9% | 6,312 | 6,255 | 6,205 | 6,086 | 6,029 |
Shares Outstanding | 0.4% | 178 | 177 | 177 | 176 | 174 |
Cashflow (Last 12 Months) | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Cashflow From Operations | 25.5% | -223 | -300 | -300 | -198 | -102 |
Share Based Compensation | -4.6% | 207 | 217 | 172 | 114 | 253 |
Cashflow From Investing | -64.8% | 74.00 | 211 | 96.00 | -719 | -1,082 |
Cashflow From Financing | 41.2% | 76.00 | 54.00 | 54.00 | 4.00 | 8.00 |
100%
78.8%
51.9%
Y-axis is the maximum loss one would have experienced if Exact Sciences was unfortunately bought at previous high price.
20.8%
40.4%
8.5%
6.6%
FIve years rolling returns for Exact Sciences.
Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
2023-03-10 | BAILLIE GIFFORD & CO | added | 2.45 | 87,764,800 | 244,147,000 | 0.25% |
2023-03-10 | VICTORY CAPITAL MANAGEMENT INC | reduced | -0.05 | 338,407 | 984,407 | -% |
2023-03-06 | Rockefeller Capital Management L.P. | reduced | -28.71 | 14,000 | 172,000 | -% |
2023-03-02 | OLIVER LAGORE VANVALIN INVESTMENT GROUP | unchanged | - | 476 | 2,476 | -% |
2023-02-28 | Voya Investment Management LLC | reduced | -0.58 | 532,655 | 1,565,660 | -% |
2023-02-27 | ST GERMAIN D J CO INC | new | - | 16,091 | 16,091 | -% |
2023-02-24 | NATIXIS | sold off | -100 | -10,880,000 | - | -% |
2023-02-22 | TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY | added | 28.11 | 1,188,000 | 2,434,000 | 0.03% |
2023-02-21 | NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | unchanged | - | 1,725 | 10,725 | -% |
2023-02-21 | NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | unchanged | - | 1,153 | 6,153 | -% |
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Feb 10, 2023 | ark investment management llc | 9.03% | 16,040,490 | SC 13G/A | |
Feb 09, 2023 | vanguard group inc | 9.71% | 17,252,465 | SC 13G/A | |
Feb 07, 2023 | blackrock inc. | 6.4% | 11,354,134 | SC 13G/A | |
Feb 06, 2023 | wellington management group llp | 5.86% | 10,404,476 | SC 13G/A | |
Sep 12, 2022 | price t rowe associates inc /md/ | 3.7% | 6,464,337 | SC 13G/A | |
Mar 10, 2022 | price t rowe associates inc /md/ | 10.7% | 18,724,736 | SC 13G/A | |
Feb 14, 2022 | price t rowe associates inc /md/ | 8.0% | 13,788,133 | SC 13G/A | |
Feb 11, 2022 | capital world investors | 2.7% | 4,682,850 | SC 13G/A | |
Feb 09, 2022 | ark investment management llc | 7.83% | 13,496,014 | SC 13G | |
Feb 04, 2022 | blackrock inc. | 5.5% | 9,497,012 | SC 13G |
Fair Value | Very Pessimistic | Pessimistic | Base Case | Optimistic | Very Optimistic |
---|---|---|---|---|---|
Very Low Inflation | 5.60 -91.69% | 7.74 -88.51% | 14.15 -79.00% | 26.51 -60.66% | 51.53 -23.52% |
Current Inflation | 5.43 -91.94% | 7.34 -89.11% | 12.90 -80.85% | 23.46 -65.18% | 44.74 -33.60% |
Very High Inflation | 5.23 -92.24% | 6.85 -89.83% | 11.41 -83.07% | 19.92 -70.44% | 36.93 -45.19% |
Date Filed | Form Type | Document | |
---|---|---|---|
Mar 17, 2023 | 424B7 | Prospectus Filed | |
Mar 17, 2023 | 8-K | Current Report | |
Mar 07, 2023 | 4 | Insider Trading | |
Mar 03, 2023 | 8-K | Current Report | |
Mar 02, 2023 | 4 | Insider Trading | |
Mar 02, 2023 | 4 | Insider Trading | |
Mar 01, 2023 | 4 | Insider Trading | |
Mar 01, 2023 | 8-K | Current Report | |
Mar 01, 2023 | 4 | Insider Trading | |
Mar 01, 2023 | 4 | Insider Trading |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
2023-03-03 | ORVILLE JACOB A | sold | -325,000 | 65.00 | -5,000 | general manager, screening |
2023-03-01 | Cunningham Everett | sold | -224,972 | 62.01 | -3,628 | chief commercial officer |
2023-03-01 | Condella Sarah | sold | -62,000 | 62.00 | -1,000 | evp, human resources |
2023-02-28 | Condella Sarah | sold | -178,715 | 61.12 | -2,924 | evp, human resources |
2023-02-28 | Conroy Kevin T | sold | -636,626 | 61.12 | -10,416 | president and ceo |
2023-02-28 | Baranick Brian | sold | -118,084 | 61.12 | -1,932 | gen. mgr., precision oncology |
2023-02-28 | Elliott Jeffrey Thomas | sold | -258,721 | 61.12 | -4,233 | chief financial officer |
2023-02-28 | ORVILLE JACOB A | sold | -411,872 | 60.2857 | -6,832 | general manager, screening |
2023-02-28 | Herriott James | sold | -134,453 | 60.4283 | -2,225 | general counsel |
2023-02-28 | COWARD D SCOTT | sold | -253,831 | 61.12 | -4,153 | - |
Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands | 12 Months Ended | ||
---|---|---|---|
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Income Statement [Abstract] | |||
Revenue | $ 2,084,279 | $ 1,767,087 | $ 1,491,391 |
Operating expenses: | |||
Cost of sales (exclusive of amortization of acquired intangible assets) | 574,394 | 458,757 | 354,324 |
Research and development | 393,418 | 385,646 | 554,052 |
Sales and marketing | 846,011 | 861,889 | 589,919 |
General and administrative | 737,304 | 801,262 | 481,393 |
Amortization of acquired intangible assets | 97,450 | 95,001 | 93,398 |
Impairment of long-lived assets | 15,969 | 20,210 | 209,666 |
Total operating expenses | 2,664,546 | 2,622,765 | 2,282,752 |
Other operating income (loss) | (13,244) | 0 | 23,665 |
Loss from operations | (593,511) | (855,678) | (767,696) |
Other income (expense) | |||
Investment income (loss), net | (19,425) | 31,778 | 6,574 |
Interest expense | (19,634) | (18,606) | (67,941) |
Total other income (expense) | (39,059) | 13,172 | (61,367) |
Net loss before tax | (632,570) | (842,506) | (829,063) |
Income tax benefit | 9,064 | 246,881 | 5,458 |
Net loss | $ (623,506) | $ (595,625) | $ (823,605) |
Net loss per share - basic (in dollars per share) | $ (3.54) | $ (3.48) | $ (5.45) |
Net loss per share - diluted (in dollars per share) | $ (3.54) | $ (3.48) | $ (5.45) |
Weighted average common shares outstanding - basic (in shares) | 176,351 | 171,348 | 151,137 |
Weighted average common shares outstanding - diluted (in shares) | 176,351 | 171,348 | 151,137 |
Consolidated Balance Sheets - USD ($) $ in Thousands | Dec. 31, 2022 | Dec. 31, 2021 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 242,493 | $ 315,471 |
Marketable securities | 389,564 | 715,005 |
Accounts receivable, net | 158,043 | 216,645 |
Inventory | 118,259 | 104,994 |
Prepaid expenses and other current assets | 73,898 | 74,122 |
Total current assets | 982,257 | 1,426,237 |
Long-term assets: | ||
Property, plant and equipment, net | 684,756 | 580,248 |
Operating lease right-of-use assets | 167,003 | 174,225 |
Goodwill | 2,346,040 | 2,335,172 |
Intangible assets, net | 1,956,240 | 2,094,411 |
Other long-term assets, net | 90,577 | 74,591 |
Total assets | 6,226,873 | 6,684,884 |
Current liabilities: | ||
Accounts payable | 74,916 | 67,829 |
Accrued liabilities | 299,216 | 398,556 |
Operating lease liabilities, current portion | 28,366 | 19,710 |
Other current liabilities | 10,249 | 30,973 |
Total current liabilities | 412,747 | 517,068 |
Convertible notes, net | 2,186,106 | 2,180,232 |
Long-term debt | 50,000 | 0 |
Other long-term liabilities | 352,459 | 417,782 |
Operating lease liabilities, less current portion | 182,399 | 182,166 |
Total liabilities | 3,183,711 | 3,297,248 |
3183711000 | ||
Stockholders’ equity: | ||
Preferred stock, $0.01 par value Authorized—5,000,000 shares issued and outstanding—no shares at December 31, 2022 and December 31, 2021 | 0 | 0 |
Common stock, $0.01 par value Authorized—400,000,000 shares issued and outstanding—177,925,631 and 173,674,067 shares at December 31, 2022 and December 31, 2021 | 1,780 | 1,738 |
Additional paid-in capital | 6,311,644 | 6,028,861 |
Accumulated other comprehensive loss | (5,236) | (1,443) |
Accumulated deficit | (3,265,026) | (2,641,520) |
Total stockholders’ equity | 3,043,162 | 3,387,636 |
Total liabilities and stockholders’ equity | $ 6,226,873 | $ 6,684,884 |